Direct consumer access Phenomix Sciences recently launched direct patient access to its MyPhenome genetic obesity test, enabling online ordering and lifestyle guidance. This creates a potential sales channel to partner with healthcare providers, payers, and digital health platforms looking to integrate genetics-informed weight management solutions.

Clinical validation momentum Active participation and presentation of MyPhenome research at major conferences (DDW 2025, Obesity Week 2025) signals strong clinical utility and broad data support. This presents opportunities to engage health systems, researchers, and pharma focused on precision obesity interventions.

Strategic partnerships Existing integrations with InformedDNA and collaborations with Mayo Clinic researchers indicate a track record of co-development and network access. BD teams can leverage these relationships to offer combined genetic testing with decision-support platforms and payer-ready bundles.

Diverse test portfolio Three-in-one MyPhenome test suite (Hungry Gut, Hungry Brain, Emotional Hunger) positions Phenomix to target multiple obesity phenotypes and behavioral drivers. This enables upsell opportunities with multi-test bundles to clinics, weight management programs, and health plans seeking personalized care pathways.

Growth and funding signals Current revenue estimates and $13M in funding indicate a scaling phase with room for strategic partnerships, channel partnerships, and pilot programs. Sales teams can pursue multi-stakeholder deals with health systems, employer programs, and payers seeking innovative obesity precision medicine solutions.